BR112023018204A2 - Método de tratamento de doenças usando antagonistas de gremlin1 - Google Patents
Método de tratamento de doenças usando antagonistas de gremlin1Info
- Publication number
- BR112023018204A2 BR112023018204A2 BR112023018204A BR112023018204A BR112023018204A2 BR 112023018204 A2 BR112023018204 A2 BR 112023018204A2 BR 112023018204 A BR112023018204 A BR 112023018204A BR 112023018204 A BR112023018204 A BR 112023018204A BR 112023018204 A2 BR112023018204 A2 BR 112023018204A2
- Authority
- BR
- Brazil
- Prior art keywords
- gremlin1
- antagonists
- treatment method
- disease treatment
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021080142 | 2021-03-11 | ||
| CN2022076516 | 2022-02-16 | ||
| PCT/CN2022/080297 WO2022188856A1 (en) | 2021-03-11 | 2022-03-11 | Method of treating diseases using gremlin1 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023018204A2 true BR112023018204A2 (pt) | 2023-10-24 |
Family
ID=83226314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023018204A BR112023018204A2 (pt) | 2021-03-11 | 2022-03-11 | Método de tratamento de doenças usando antagonistas de gremlin1 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240190950A1 (https=) |
| EP (1) | EP4304646A4 (https=) |
| JP (1) | JP2024513692A (https=) |
| KR (1) | KR20230156936A (https=) |
| CN (1) | CN116940380A (https=) |
| AU (1) | AU2022233762A1 (https=) |
| BR (1) | BR112023018204A2 (https=) |
| CA (1) | CA3213121A1 (https=) |
| MX (1) | MX2023010594A (https=) |
| TW (1) | TW202300527A (https=) |
| WO (1) | WO2022188856A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022152290A1 (en) * | 2021-01-18 | 2022-07-21 | Suzhou Transcenta Therapeutics Co., Ltd. | Novel anti-gremlin1 antibodies |
| CN120957750A (zh) * | 2023-04-13 | 2025-11-14 | 苏州创胜医药集团有限公司 | 用于治疗癌症的涉及grem1拮抗剂的组合疗法 |
| CN117801109B (zh) * | 2024-03-01 | 2024-05-03 | 再少年(北京)生物科技有限公司 | iPS诱导定向分化成内皮祖细胞的方法及应用 |
| CN119746060B (zh) * | 2025-03-07 | 2025-09-16 | 南昌大学第一附属医院 | 一种树突状细胞疫苗制剂及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2826790B1 (en) * | 2012-03-15 | 2019-02-13 | SNU R&DB Foundation | Anti-gremlin-1 antibody |
| EA201591762A1 (ru) * | 2013-03-14 | 2015-12-30 | Ридженерон Фармасьютикалз, Инк. | Человеческие антитела к grem1 |
| CA3030582A1 (en) * | 2015-07-22 | 2017-01-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Compounds and uses thereof in the treatment of cancers and other medical conditions |
| GB201621635D0 (en) * | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| MX2020013808A (es) * | 2018-06-18 | 2021-05-27 | UCB Biopharma SRL | Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer. |
| WO2022152290A1 (en) * | 2021-01-18 | 2022-07-21 | Suzhou Transcenta Therapeutics Co., Ltd. | Novel anti-gremlin1 antibodies |
-
2022
- 2022-03-11 EP EP22766378.8A patent/EP4304646A4/en active Pending
- 2022-03-11 MX MX2023010594A patent/MX2023010594A/es unknown
- 2022-03-11 CA CA3213121A patent/CA3213121A1/en active Pending
- 2022-03-11 TW TW111109016A patent/TW202300527A/zh unknown
- 2022-03-11 AU AU2022233762A patent/AU2022233762A1/en active Pending
- 2022-03-11 WO PCT/CN2022/080297 patent/WO2022188856A1/en not_active Ceased
- 2022-03-11 JP JP2023555769A patent/JP2024513692A/ja active Pending
- 2022-03-11 US US18/549,928 patent/US20240190950A1/en active Pending
- 2022-03-11 BR BR112023018204A patent/BR112023018204A2/pt unknown
- 2022-03-11 CN CN202280020454.8A patent/CN116940380A/zh active Pending
- 2022-03-11 KR KR1020237034659A patent/KR20230156936A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022188856A1 (en) | 2022-09-15 |
| AU2022233762A1 (en) | 2023-10-05 |
| TW202300527A (zh) | 2023-01-01 |
| EP4304646A1 (en) | 2024-01-17 |
| KR20230156936A (ko) | 2023-11-15 |
| CA3213121A1 (en) | 2022-09-15 |
| US20240190950A1 (en) | 2024-06-13 |
| CN116940380A (zh) | 2023-10-24 |
| EP4304646A4 (en) | 2025-05-28 |
| JP2024513692A (ja) | 2024-03-27 |
| MX2023010594A (es) | 2023-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023018204A2 (pt) | Método de tratamento de doenças usando antagonistas de gremlin1 | |
| MX2022002682A (es) | Anticuerpos anti-cd73. | |
| PH12019501663A1 (en) | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate | |
| PH12022550578A1 (en) | Method for identifying responders to smarca2/4 degraders | |
| EP4085919A3 (en) | Compositions and methods to treat cancer | |
| BR112018011029A2 (pt) | métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits | |
| BR112023005160A2 (pt) | Terapia de combinação para o tratamento de câncer | |
| BRPI0515352A (pt) | métodos para tratamento de cáncer | |
| MX2022010693A (es) | Compuestos, composiciones y metodos para inhibidores de la proteina quinasa que interactua con el receptor i para el tratamiento de enfermedades. | |
| EA201890957A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей | |
| EA201590144A1 (ru) | Rspo3-связывающие агенты и их применение | |
| BR112018075660A2 (pt) | métodos de tratamento de câncer de pâncreas | |
| BR112023003688A2 (pt) | Métodos, terapias e usos para tratar câncer | |
| MX2019006331A (es) | Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos. | |
| BR112022001690A2 (pt) | Tratamento de tumores imunes evasivos | |
| MX2019012176A (es) | Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral. | |
| MX2023002106A (es) | Anticuerpos fgfr3 y metodos de uso. | |
| WO2020209988A3 (en) | Diverse marker panel for ptsd diagnosis and treatment | |
| MX2020005473A (es) | Anticuerpos humanizados que se dirigen al factor tisular humano. | |
| ZA201907371B (en) | Methods and compositions for treating allergic ocular diseases | |
| JOP20240132A1 (ar) | أجسام مضادة لـ c3 وشظايا ارتباط بمولد الضد منها واستخداماتها لعلاج العين أو الأمراض العينية | |
| BR112018068625A2 (pt) | métodos de tratamento ou prevenção de doença de enxerto contra hospedeiro | |
| CO2021005234A2 (es) | Métodos de tratamiento | |
| CO2021005207A2 (es) | Métodos de tratamiento | |
| BR112023006954A2 (pt) | Indução de ferroptose para terapia de câncer |